"Cyclin-Dependent Kinase Inhibitor p27" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin-dependent kinase inhibitor that coordinates the activation of CYCLIN and CYCLIN-DEPENDENT KINASES during the CELL CYCLE. It interacts with active CYCLIN D complexed to CYCLIN-DEPENDENT KINASE 4 in proliferating cells, while in arrested cells it binds and inhibits CYCLIN E complexed to CYCLIN-DEPENDENT KINASE 2.
Descriptor ID |
D050760
|
MeSH Number(s) |
D12.644.360.225.600 D12.776.167.187.600 D12.776.476.225.600 D12.776.624.776.355.600
|
Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p27- Cyclin-Dependent Kinase Inhibitor p27
- Cyclin Dependent Kinase Inhibitor p27
- CDKN4 Protein
- p27 CDK Inhibitor
- CDK Inhibitor, p27
- p27 Kip1 Protein
- Kip1 Protein, p27
- CDKN1B Protein
- p27Kip1 Protein
- CDK Inhibitor p27
- p27, CDK Inhibitor
- Cyclin-Dependent Kinase Inhibitor 1B
- Cyclin Dependent Kinase Inhibitor 1B
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p27".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p27".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p27" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p27" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p27" by people in Profiles.
-
CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system-New mode of action for caffeine. PLoS Biol. 2018 06; 16(6):e2004408.
-
Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 2006 Jan 15; 66(2):1114-22.